このエントリーをはてなブックマークに追加


ID 68737
フルテキストURL
fulltext.pdf 3.05 MB
著者
Haratake, Tomoka Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Nishimura, Midori Filiz Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Nishikori, Asami Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Gonzalez, Michael V. Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
Ennishi, Daisuke Center for Comprehensive Genomic Medicine, Okayama University Hospital
Lai, You Cheng Department of Medical Biotechnology and Laboratory Science, Chang Gung University
Ochi, Sayaka Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Tsunoda, Manaka Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Fajgenbaum, David C. Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
van Rhee, Frits Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
Momose, Shuji Department of Pathology, Saitama Medical Center, Saitama Medical University
Sato, Yasuharu Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences ORCID Kaken ID researchmap
抄録
Idiopathic multicentric Castleman disease is a rare lymphoproliferative disorder that is clinically classified into idiopathic plasmacytic lymphadenopathy (IPL); thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO); and not otherwise specified (NOS). Although each subtype shows varying degrees of hypervascularity, no statistical data on the degree of vascularization have been reported. Additionally, the mechanisms underlying vascularization in each clinical subtype are poorly understood. Here, we aimed to clarify these mechanisms by evaluating the histopathological characteristics of each clinical subtype across 37 patients and performing a whole-transcriptome analysis focusing on angiogenesis-related gene expression. Histologically, TAFRO and NOS exhibited a significantly higher degree of vascularization than IPL (IPL vs TAFRO, P < .001; IPL vs NOS, P = .002). In addition, the germinal centers (GCs) were significantly more atrophic in TAFRO than in IPL. In TAFRO and NOS, “whirlpool vessels” in GCs were seen in most cases (TAFRO, 9/9, 100%; NOS, 6/8, 75%) but not in IPL (IPL vs TAFRO, P < .001; IPL vs NOS, P = .007). Likewise, immunostaining for Ets-related gene revealed higher levels in endothelial cells of GCs in TAFRO than in IPL (P = .014), and TAFRO and NOS were associated with a significantly higher number of endothelial cells in interfollicular areas compared with that in IPL (TAFRO vs IPL, P < .001; NOS vs IPL, P = .002). Gene expression analysis revealed that the PI3K–Akt signaling pathway was significantly enriched in the TAFRO and NOS (TAFRO/NOS) groups. This pathway, which may be activated by vascular endothelial growth factor A and some integrins, is known to affect angiogenesis by increasing vascular permeability, which may explain the clinical manifestations of anasarca and/or fluid retention in TAFRO/NOS. These results suggest that the PI3K–Akt pathway plays an important role in the pathogenesis of TAFRO/NOS.
キーワード
idiopathic multicentric Castleman disease
integrin subunit alpha 5
PI3K–Akt signaling pathway
platelet-derived growth factor receptor beta
vascular endothelial growth factor A
vascularity
発行日
2025-08
出版物タイトル
Modern Pathology
38巻
8号
出版者
Elsevier BV
開始ページ
100782
ISSN
0893-3952
NCID
AA1067307X
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2025 THE AUTHORS.
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1016/j.modpat.2025.100782
ライセンス
http://creativecommons.org/licenses/by/4.0/
助成機関名
Japan Society for the Promotion of Science
Ministry of Health, Labour and Welfare
Japan Agency for Medical Research and Development
助成番号
JP23K14476
JP24KK0172
JP25K02476
JPMH23FC1025
JP24ek0109589